Recruiting Thrombocytopenia Studies in Stanford
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...
About Thrombocytopenia Clinical Trials in Stanford
Thrombocytopenia is a condition characterized by abnormally low levels of platelets, which help blood clot. Immune thrombocytopenia (ITP) is a common autoimmune cause. Treatment may include corticosteroids, immunoglobulins, thrombopoietin receptor agonists, and splenectomy.
There are currently 2 thrombocytopenia clinical trials recruiting participants in Stanford, CA. These studies are seeking a combined 118 participants. Research is being sponsored by Veralox Therapeutics, Eli Lilly and Company. Clinical trial participation is free and participants receive study-related medical care at no cost.
Thrombocytopenia Clinical Trials in Stanford — FAQ
Are there thrombocytopenia clinical trials in Stanford?
Yes, there are 2 thrombocytopenia clinical trials currently recruiting in Stanford, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Stanford?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Stanford research site will contact you about next steps.
Are clinical trials in Stanford free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Stanford studies also compensate for your time and travel.
What thrombocytopenia treatments are being tested?
The 2 active trials in Stanford are testing new therapies including novel drugs, biologics, and treatment approaches for thrombocytopenia.
Data updated March 2, 2026 from ClinicalTrials.gov